Anna A. Kudrjavtseva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna A. Kudrjavtseva has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya A. Sokolova
Sechenov First Moscow State Medical University (Sechenov University)
10 shared publications - Dmitry A. Napalkov
Sechenov First Moscow State Medical University (Sechenov University)
10 shared publications - Маргарита Павловна Заикина
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Alena I. Skripka
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - E. V. Kolpachkova
JSC "Medsi" Company Group
3 shared publications - Z. A. Gebekova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 139-145
Use of an individual NT-proBNP value calculator in the diagnosis of heart failure with preserved ejection fraction
Aim. To develop an online calculator of individual NT-proBNP thresholds to diagnose heart failure with preserved ejection fraction (HFpEF) and to pilot it in clinical practice. Material and methods. At the first stage, an online calculator that computes a personalised NT-proBNP threshold based on age, sex, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI), and the presence of atrial fibrillation was developed. A total of 128 patients (50% women; median age, 71 years) with HFpEF hospitalised at University Clinical Hospital No. 1, Sechenov University, between January and August 2024 were enrolled to validate the calculator. Diagnoses based on guideline-recommended NT-proBNP cutoffs were compared with diagnoses incorporating individualised thresholds from the calculator. Agreement between methods was assessed using Cohen’s kappa, and differences in diagnosis rates were evaluated with McNemar’s test. Results . When comparing diagnoses based on standard NT-proBNP thresholds with those using individualised values, the diagnosis changed in 38 cases (29.7%): HFpEF was established in 30 patients and excluded in 8. Cohen’s kappa was 0.35. The difference between approaches was statistically significant (p=0.0005). The greatest diagnostic discrepancies were observed in patients younger than 60 years and in those with BMI 30-34 kg/m² and ≥40 kg/m²; statistically significant differences in diagnosis frequency were found only for patients with BMI 30-34 kg/m² (k=0.38, p Conclusion. NT-proBNP remains a key biomarker in HFpEF diagnosis; however, patient sex, age, and comorbidities affect its circulating levels. We therefore propose using our online calculator to derive individualized NT-proBNP thresholds for HFpEF diagnosis to reduce diagnostic errors, initiate treatment in a timely manner, and avoid unnecessary medication.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 139-145
Open AccessUse of an individual NT-proBNP value calculator in the diagnosis of heart failure with preserved ejection fraction
Aim. To develop an online calculator of individual NT-proBNP thresholds to diagnose heart failure with preserved ejection fraction (HFpEF) and to pilot it in clinical practice. Material and methods. At the first stage, an online calculator that computes a personalised NT-proBNP threshold based on age, sex, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI), and the presence of atrial fibrillation was developed. A total of 128 patients (50% women; median age, 71 years) with HFpEF hospitalised at University Clinical Hospital No. 1, Sechenov University, between January and August 2024 were enrolled to validate the calculator. Diagnoses based on guideline-recommended NT-proBNP cutoffs were compared with diagnoses incorporating individualised thresholds from the calculator. Agreement between methods was assessed using Cohen’s kappa, and differences in diagnosis rates were evaluated with McNemar’s test. Results . When comparing diagnoses based on standard NT-proBNP thresholds with those using individualised values, the diagnosis changed in 38 cases (29.7%): HFpEF was established in 30 patients and excluded in 8. Cohen’s kappa was 0.35. The difference between approaches was statistically significant (p=0.0005). The greatest diagnostic discrepancies were observed in patients younger than 60 years and in those with BMI 30-34 kg/m² and ≥40 kg/m²; statistically significant differences in diagnosis frequency were found only for patients with BMI 30-34 kg/m² (k=0.38, p Conclusion. NT-proBNP remains a key biomarker in HFpEF diagnosis; however, patient sex, age, and comorbidities affect its circulating levels. We therefore propose using our online calculator to derive individualized NT-proBNP thresholds for HFpEF diagnosis to reduce diagnostic errors, initiate treatment in a timely manner, and avoid unnecessary medication.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 197-203
Secondary arterial hypertension due to excessive vitamin D intake and hyperparathyroidism: a clinical case
This clinical case report describes the development of intoxication symptoms (nausea, muscle cramps, generalised weakness) and instability of blood pressure associated with long-term uncontrolled intake of high-dose vitamin D (up to 35,000 IU per week) in a 68-year-old female patient with comorbid conditions: secondary arterial hypertension, primary hyperparathyroidism, and chronic kidney disease stage C3a. Laboratory analysis revealed a typical triad of abnormalities: hypercalcemia (total calcium up to 2.82 mmol/L), elevated parathyroid hormone level (115.4 pg/mL), and a high serum 25(OH)D concentration (70.6 ng/mL). Key evidence of the iatrogenic nature of the symptoms was the complete resolution of complaints and normalisation of blood pressure on the previous antihypertensive therapy following discontinuation of vitamin D intake, as well as recurrence of symptoms upon resumption of vitamin D supplements, even at a lower dose (14,000 IU/day). A notable feature of this case is the development of toxic effects at a serum 25(OH)D level only slightly above the normal range, which underscores the importance of identifying adverse effects when prescribing therapy to patients with comorbidities. This observation highlights the necessity for thorough laboratory monitoring (calcium, parathyroid hormone, 25(OH)D, renal function parameters) prior to and during vitamin D supplementation, particularly in patients with hyperparathyroidism and chronic kidney disease.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 197-203
Secondary arterial hypertension due to excessive vitamin D intake and hyperparathyroidism: a clinical case
This clinical case report describes the development of intoxication symptoms (nausea, muscle cramps, generalised weakness) and instability of blood pressure associated with long-term uncontrolled intake of high-dose vitamin D (up to 35,000 IU per week) in a 68-year-old female patient with comorbid conditions: secondary arterial hypertension, primary hyperparathyroidism, and chronic kidney disease stage C3a. Laboratory analysis revealed a typical triad of abnormalities: hypercalcemia (total calcium up to 2.82 mmol/L), elevated parathyroid hormone level (115.4 pg/mL), and a high serum 25(OH)D concentration (70.6 ng/mL). Key evidence of the iatrogenic nature of the symptoms was the complete resolution of complaints and normalisation of blood pressure on the previous antihypertensive therapy following discontinuation of vitamin D intake, as well as recurrence of symptoms upon resumption of vitamin D supplements, even at a lower dose (14,000 IU/day). A notable feature of this case is the development of toxic effects at a serum 25(OH)D level only slightly above the normal range, which underscores the importance of identifying adverse effects when prescribing therapy to patients with comorbidities. This observation highlights the necessity for thorough laboratory monitoring (calcium, parathyroid hormone, 25(OH)D, renal function parameters) prior to and during vitamin D supplementation, particularly in patients with hyperparathyroidism and chronic kidney disease.
- Open Access
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in I.P. Pavlov Russian Medical Biological Herald
- Vol. 34 (1) , 127-134
Syncope in an adult patient with comorbidity: from syndrome to diagnosis of pertussis infection
BACKGROUND: In recent years, the morbidity with pertussis has shown a significant growth among both children and adults worldwide. Complications and fatalities are more commonly recorded among children, although adults, especially those with underlying pathology, are also at risk. In addition, in adult patients, the disease is characterized by attenuated forms and comorbidities, which hampers timely diagnosis and treatment and contributes to the development of complications. This article presents a clinical case of pertussis in a patient with morbid obesity, uncontrolled hypertension, impaired glucose tolerance, vasomotor rhinitis, and severe obstructive sleep apnea syndrome (OSAS). A notable feature of this case is the development of bettolepsy a syncopal state occurring at the height of a coughing fit, which resulted in trauma to the patient. The absence of a prodromal period of syncope and the presence of several significant comorbidities necessitated a comprehensive diagnostic search. A medical history revealed contact with children with pertussis. Serological testing confirmed pertussis infection. Instrumental studies, including cardiorespiratory sleep monitoring, electroencephalography, magnetic resonance imaging of the head, duplex scanning of the brachiocephalic arteries, and computed tomography of the chest, were performed. Based on these results, cardiac and neurological causes of syncope were excluded, suggesting pertussis infection as the cause of syncope. Prescribed therapy included cough suppressants, reinstatement of CPAP therapy after consultation with an otolaryngologist, and nasal breathing correction for OSAS, which led to improvement in the patient's condition. CONCLUSION: This case highlights the need to include pertussis in the differential diagnosis of adult patients with a persistent cough, even in the absence of the classic clinical picture. This is especially important in a patient with comorbidities, such as OSAS, which can aggravate the course of pertussis and lead to life-threatening complications. Timely diagnosis and appropriate treatment are essential to prevent an adverse outcome.
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in I.P. Pavlov Russian Medical Biological Herald
- Vol. 34 (1) , 127-134
Open AccessSyncope in an adult patient with comorbidity: from syndrome to diagnosis of pertussis infection
BACKGROUND: In recent years, the morbidity with pertussis has shown a significant growth among both children and adults worldwide. Complications and fatalities are more commonly recorded among children, although adults, especially those with underlying pathology, are also at risk. In addition, in adult patients, the disease is characterized by attenuated forms and comorbidities, which hampers timely diagnosis and treatment and contributes to the development of complications. This article presents a clinical case of pertussis in a patient with morbid obesity, uncontrolled hypertension, impaired glucose tolerance, vasomotor rhinitis, and severe obstructive sleep apnea syndrome (OSAS). A notable feature of this case is the development of bettolepsy a syncopal state occurring at the height of a coughing fit, which resulted in trauma to the patient. The absence of a prodromal period of syncope and the presence of several significant comorbidities necessitated a comprehensive diagnostic search. A medical history revealed contact with children with pertussis. Serological testing confirmed pertussis infection. Instrumental studies, including cardiorespiratory sleep monitoring, electroencephalography, magnetic resonance imaging of the head, duplex scanning of the brachiocephalic arteries, and computed tomography of the chest, were performed. Based on these results, cardiac and neurological causes of syncope were excluded, suggesting pertussis infection as the cause of syncope. Prescribed therapy included cough suppressants, reinstatement of CPAP therapy after consultation with an otolaryngologist, and nasal breathing correction for OSAS, which led to improvement in the patient's condition. CONCLUSION: This case highlights the need to include pertussis in the differential diagnosis of adult patients with a persistent cough, even in the absence of the classic clinical picture. This is especially important in a patient with comorbidities, such as OSAS, which can aggravate the course of pertussis and lead to life-threatening complications. Timely diagnosis and appropriate treatment are essential to prevent an adverse outcome.
- Open Access
- 14 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (12) , 1018-1022
A clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome
The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.
- 14 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (12) , 1018-1022
Open AccessA clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome
The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.
- Open Access
- 7 August 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (2) , 126-131
Features of the “Thrombodynamics” test in patients with cancer
Introduction: Thromboembolic complications are one of the leading causes of mortality among cancer patients, significantly worsening their clinical condition and prognosis. Effective diagnostic methods for hypercoagulation and prevention of thromboembolic complications are essential for oncological patients. The “Thrombodynamics” test is an integrative tool that allows for a more precise assessment of the fibrin clot formation process in conditions that closely mimic physiological conditions. Aim: To evaluate the features of hemostasis in patients with cancer using the “Thrombodynamics” test and to identify potential differences in thrombogenic activity depending on the tumor localization. Materials and methods: The study included 100 patients, aged (65 ± 10.6) years, with 75 patients forming the main group (patients with histologically confirmed cancer) and 25 patients forming the control group (healthy individuals). Patients in both groups were matched by gender, age, and comorbidities. The “Thrombodynamics” test was performed according to the standard protocol using the “Thrombodynamics Recorder T-2” system (SDL RT T-2, GemaKor, Moscow, Russia). Results: The results of the study showed that patients with malignant neoplasms have pronounced hypercoagulability, which is confirmed by an increase in the growth rate of the fibrin clot, the initial growth rate and the clot size compared to the control group. Although the differences in the clot growth delay time were insignificant, all other parameters in patients with malignant neoplasms exceeded the reference values, indicating increased thrombogenic activity. И: The Thrombodynamics test shows hypercoagulation in patients with cancer. Further studies are needed to better understand the mechanisms of hypercoagulability in various types of cancer and optimize the methods of TEC prevention in these patients.
- 7 August 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (2) , 126-131
Open AccessFeatures of the “Thrombodynamics” test in patients with cancer
Introduction: Thromboembolic complications are one of the leading causes of mortality among cancer patients, significantly worsening their clinical condition and prognosis. Effective diagnostic methods for hypercoagulation and prevention of thromboembolic complications are essential for oncological patients. The “Thrombodynamics” test is an integrative tool that allows for a more precise assessment of the fibrin clot formation process in conditions that closely mimic physiological conditions. Aim: To evaluate the features of hemostasis in patients with cancer using the “Thrombodynamics” test and to identify potential differences in thrombogenic activity depending on the tumor localization. Materials and methods: The study included 100 patients, aged (65 ± 10.6) years, with 75 patients forming the main group (patients with histologically confirmed cancer) and 25 patients forming the control group (healthy individuals). Patients in both groups were matched by gender, age, and comorbidities. The “Thrombodynamics” test was performed according to the standard protocol using the “Thrombodynamics Recorder T-2” system (SDL RT T-2, GemaKor, Moscow, Russia). Results: The results of the study showed that patients with malignant neoplasms have pronounced hypercoagulability, which is confirmed by an increase in the growth rate of the fibrin clot, the initial growth rate and the clot size compared to the control group. Although the differences in the clot growth delay time were insignificant, all other parameters in patients with malignant neoplasms exceeded the reference values, indicating increased thrombogenic activity. И: The Thrombodynamics test shows hypercoagulation in patients with cancer. Further studies are needed to better understand the mechanisms of hypercoagulability in various types of cancer and optimize the methods of TEC prevention in these patients.
- Open Access
- 28 February 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (1) , 169-179
IMPLICATION OF CARDIOVASCULAR PATHOLOGY ON THE RISKS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS
HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.
- 28 February 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (1) , 169-179
Open AccessIMPLICATION OF CARDIOVASCULAR PATHOLOGY ON THE RISKS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS
HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.
- Open Access
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Open AccessNephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.
- Open Access
- 27 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3S) , 5790
Management of comorbid patients with chronic kidney disease and decline in renal function: a case report
Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and sodiumglucose cotransporter 2 inhibitors. However, deterioration of kidney function is still common in these patients, especially in the presence of risk factors. This case illustrates the decline in renal function in a patient with obesity, uncontrolled hypertension, type 2 diabetes and atrial fibrillation. The management strategy for such patients is given.
- 27 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3S) , 5790
Open AccessManagement of comorbid patients with chronic kidney disease and decline in renal function: a case report
Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and sodiumglucose cotransporter 2 inhibitors. However, deterioration of kidney function is still common in these patients, especially in the presence of risk factors. This case illustrates the decline in renal function in a patient with obesity, uncontrolled hypertension, type 2 diabetes and atrial fibrillation. The management strategy for such patients is given.
- Open Access
- 23 April 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (2) , 221-226
Comparative placebo-controlled study on the effect of dietary supplements containing omega-3 polyunsaturated fatty acids on hemodynamics and lipid metabolism in postmenopausal women
Aim. To study the effect of dietary supplements containing omega-3 polyunsaturated fatty acids (Omega-3 PUFAs) on the parameters of ambulatory blood pressure monitoring (ABPM), 24-hour electrocardiogram (HM-ECG), and lipid profile in postmenopausal women.Material and methods. The study involved 95 postmenopausal women with a mean age of 55.9±6.0 years, without cardiovascular complications, type 2 diabetes mellitus and atrial fibrillation/flutter. The patients were divided into the main group (n=49; dietary supplement with Omega-3 PUFAs 1 g 2 times/day — content of Omega-3 PUFAs at least 30%) and the placebo group (n=46; taking capsules with vegetable oil). 17 (34.7%) patients from the main group and 18 (39.1%) patients from the placebo group took constant antihypertensive therapy, 7 (14.3%) of patients from the main group and 7 (15.2%) patients from the placebo group took constant lipid- lowering therapy. The patients did not undergo any adjustment of antihypertensive and lipid-l owering therapy during observation. The patients underwent 24-hour blood pressure and electrocardiogram monitoring, and a lipid profile evaluation at the initial visit and after 3 months.Results. It was statistically registered a significant decrease in average daily diastolic BP according to ABPM data by 1.8 mmHg. Art. (p=0.03), as well as the average daily heart rate according to HM-ECG data by 1.9 beats per minute (p=0.04) in the main group after 3 months. LDL levels tended to decrease (p=0.07) in the mail group. There were no statistically significant changes in the average daily systolic blood pressure according to ABPM, the number of supraventricular and ventricular heart rhythm disturbances, or the lipid profile (TC, LDL, triglycerides, HDL) in both groups.Conclusion. The dietary supplements containing Omega-3 PUFAs in postmenopausal women significantly reduces the level of daily diastolic blood pressure and daily heart rate without significant effect on lipid profile.
- 23 April 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (2) , 221-226
Open AccessComparative placebo-controlled study on the effect of dietary supplements containing omega-3 polyunsaturated fatty acids on hemodynamics and lipid metabolism in postmenopausal women
Aim. To study the effect of dietary supplements containing omega-3 polyunsaturated fatty acids (Omega-3 PUFAs) on the parameters of ambulatory blood pressure monitoring (ABPM), 24-hour electrocardiogram (HM-ECG), and lipid profile in postmenopausal women.Material and methods. The study involved 95 postmenopausal women with a mean age of 55.9±6.0 years, without cardiovascular complications, type 2 diabetes mellitus and atrial fibrillation/flutter. The patients were divided into the main group (n=49; dietary supplement with Omega-3 PUFAs 1 g 2 times/day — content of Omega-3 PUFAs at least 30%) and the placebo group (n=46; taking capsules with vegetable oil). 17 (34.7%) patients from the main group and 18 (39.1%) patients from the placebo group took constant antihypertensive therapy, 7 (14.3%) of patients from the main group and 7 (15.2%) patients from the placebo group took constant lipid- lowering therapy. The patients did not undergo any adjustment of antihypertensive and lipid-l owering therapy during observation. The patients underwent 24-hour blood pressure and electrocardiogram monitoring, and a lipid profile evaluation at the initial visit and after 3 months.Results. It was statistically registered a significant decrease in average daily diastolic BP according to ABPM data by 1.8 mmHg. Art. (p=0.03), as well as the average daily heart rate according to HM-ECG data by 1.9 beats per minute (p=0.04) in the main group after 3 months. LDL levels tended to decrease (p=0.07) in the mail group. There were no statistically significant changes in the average daily systolic blood pressure according to ABPM, the number of supraventricular and ventricular heart rhythm disturbances, or the lipid profile (TC, LDL, triglycerides, HDL) in both groups.Conclusion. The dietary supplements containing Omega-3 PUFAs in postmenopausal women significantly reduces the level of daily diastolic blood pressure and daily heart rate without significant effect on lipid profile.
- Open Access
- 27 July 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (3) , 248-253
Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report
The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard doses, which requires a thorough personalized approach. The article presents a clinical case of the development of spontaneous hematomas on the skin of the upper and lower extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient with AF without impaired renal and hepatic function. Due to the increase in the residual plasma concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed. A pharmacogenetic study did not reveal significant gene polymorphisms associated with the metabolism of rivaroxaban. However, TD allowed us to confirm the presence of significant hypocoagulation at the peak of the residual blood concentration of the drug in the blood, which could cause recurrent hemorrhagic events in the patient. In addition, the patient is taking amiodarone at a dosage of 200 mg per day, which does not allow us to rule out drug-drug interaction, despite the inconsistency of the literature data.
- 27 July 2023
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 19 (3) , 248-253
Open AccessRecurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report
The question of the safety of direct oral anticoagulants (DOACs), despite their high efficacy in the prevention of thrombotic events in atrial fibrillation (AF), remains relevant due to the risk of developing hemorrhagic events while taking standard doses, which requires a thorough personalized approach. The article presents a clinical case of the development of spontaneous hematomas on the skin of the upper and lower extremities and hemarthrosis of the knee joint while taking 20 mg of rivaroxaban in a 72-year-old patient with AF without impaired renal and hepatic function. Due to the increase in the residual plasma concentration of rivaroxaban, a pharmacogenetic study and the Thrombodynamics (TD) test were performed. A pharmacogenetic study did not reveal significant gene polymorphisms associated with the metabolism of rivaroxaban. However, TD allowed us to confirm the presence of significant hypocoagulation at the peak of the residual blood concentration of the drug in the blood, which could cause recurrent hemorrhagic events in the patient. In addition, the patient is taking amiodarone at a dosage of 200 mg per day, which does not allow us to rule out drug-drug interaction, despite the inconsistency of the literature data.